Rallybio Corporation (RLYB) Stock Analysis & Investment Frameworks
Rallybio Corporation (RLYB) stock analysis on Invetso. Review Rallybio Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Rallybio Corporation Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Rallybio Corporation Key Financial Metrics
- Market Cap: $84.04M
- Revenue: $858000.00
- ROE: 36.35%
- ROIC: -20.82%
- Dividend Yield: 86.87%
About Rallybio Corporation
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Rallybio Corporation Investment Frameworks
Invetso analyzes Rallybio Corporation (RLYB) across the following frameworks:
- Rallybio Corporation 10Y Growth Potential
- Rallybio Corporation Scenario Analysis
- Rallybio Corporation Risks & Opportunities
- Rallybio Corporation Economic Moat
- Rallybio Corporation Business Model
- Rallybio Corporation Management
- Rallybio Corporation SWOT Analysis
- Rallybio Corporation Porter's 5 Forces
- Rallybio Corporation PESTLE Analysis
- Rallybio Corporation ESG Analysis